A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

• Status: Not yet recruiting
• Trial end date: 2024-11-12
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this post approval pragmatic clinical study is to see how well semaglutide lowers body weight compared to other medication on the market used to treat obesity, across three US-based employers. These employers represent employees of diverse demography and job functions including hospitality, clerical, administrative, housekeeping, maintenance, and specialised employees across a range of socioeconomic and educational backgrounds. The study will also look at how weight loss affects physical functioning, quality of life and ability to work. It will also gather information on how satisfied participants are with the medication they take. Participants will either receive semaglutide or one of 4 approved anti-obesity medication (Xenical/Qsymia/Contrave/Saxenda).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Bupropion; Liraglutide; Naltrexone; Orlistat; Phentermine; Topiramate

Criteria

Inclusion Criteria:

• Body mass index (BMI) greater than equal to 30.0 kilogram per meter square (kg/m^2).

• Employed at randomisation by one of the selected employers and expecting to be so for the duration of the study.

Exclusion Criteria:

• Known or suspected hypersensitivity or contraindications to Wegovy or related products according to the label.

• Known or suspected hypersensitivity or contraindications to all of the other Anti-Obesity Medications (AOMs) for chronic weight management (Xenical, Qsymia, Contrave, and Saxenda) or related products according to the labels.

• Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.

• History of type 1 or type 2 diabetes mellitus.

• Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.